Dinoprost


Concise Prescribing Info
Indications/Uses
Pregnancy termination in the 2nd trimester.
Dosage/Direction for Use
Adult : Intra-amniotic 40 mg into the amniotic sac, followed by 10-40 mg 24 hr later if needed.
Dosage Details
Intra-amniotic
Pregnancy termination in the 2nd trimester
Adult: 40 mg by slowly injecting 8 ml of solution containing 5 mg/ml into the amniotic sac; give a further dose of 10-40 mg after 24 hr if the membranes are still intact.
Contraindications
Pelvic infection; history of pelvic inflammatory disease. Active cardiac, pulmonary, renal or hepatic disease. Smoker.
Special Precautions
Glaucoma or raised intraocular pressure, asthma or a history of asthma, epilepsy or a history of epilepsy, hepatic or renal dysfunction, CV disease. Do not administer by the myometrial route. Do not administer by the extraamniotic route in patients with cervicitis or vaginal infections. Monitor uterine activity, foetal status, cervical dilatation progress. In the induction of labor, carefully evaluate cephalopelvic relationships before use. Possibility of uterine rupture. Caution in patients with membrane rupture.
Adverse Reactions
Bronchoconstriction; nausea; vomiting; diarrhoea; abdominal pain; flushing; shivering; headache; dizziness; hypotension; sudden CV collapse; hypertension; hypersensitivity reactions; convulsions; EEG changes; local tissue irritation; erythema; pyrexia; raised white cell count; local infection; excessive uterine activity; uterine rupture; cervical laceration and rupture; foetal distress and rarely fetal death.
Drug Interactions
Potentiates uteronic effect of oxytocin.
Action
Description: Dinoprost is a prostaglandin with actions on smooth muscles. It induces contraction of uterine muscles and acts predominantly as a vasoconstrictor on blood vessels and a bronchoconstrictor on bronchial muscles.
Disclaimer: This information is independently developed by MIMS based on Dinoprost from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in